system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
appeal. 1.75 "Variant" means [***]. 1.76 "Xencor [***]" means a [***]. 1.77 "Xencor Invention" means an Invention that is Invented solely or jointly with a Third Party, by or on behalf of Xencor or its Affiliates. 1.78 "Xencor Know-How" means any and all Know-How, whether or not patented or patentable, (i) to the extent Controlled by Xencor or its Affiliates as of the Effective Date, or, if transferred to Aimmune thereafter during the Term of this Agreement, and that is necessary in connection with the Development, Manufacture, Commercialization or other use of the Antibody or Product or (ii) constituting a Xencor Invention. Notwithstanding the foregoing, in all cases, Xencor Know-How does not include (a) [***], (b) [***], (c) [***], (d) [***], (e) [***], or (f) [***]. 1.79 "Xencor General Patent" means (i) the Patents identified on Schedule 1.79, including patents issuing from any patent application set forth on Schedule 1.79, (ii) with respect to such Patents set forth on Schedule 1.79, all provisional applications, substitutions, continuations, continuations-in-part, divisionals, renewals, patents-of-addition, reissues, reexaminations and extensions, (iii) all international and domestic counterparts of any of the foregoing, and (iv) any other Patents Controlled by Xencor that claim inventions necessary for the Development, Manufacture, Commercialization or other use of the Antibody or Product as the Antibody and Product exist as of the Effective Date. 1.80 "Xencor Patent" means Xencor General Patents and Xencor Product Specific Patents. 1.81 "Xencor Product Specific Patent" means (i) the Patents identified on Schedule 1.81, including patents issuing from any patent application set forth on Schedule 1.81, (ii) with respect to all Patents set forth on Schedule 1.81, all provisional applications, substitutions, continuations, continuations- in-part, divisionals, renewals, patents-of-addition, reissues, reexaminations and extensions, (iii) any [***], and (iv) all international and domestic counterparts of any of the foregoing. 1.82 "Xencor Technology" means Xencor Know-How and Xencor Patents. 12 Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020 1.83 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement: ARTICLE 2 LICENSES 2.1 Grant to Aimmune. Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement. 2.2 Additional Licensing Provisions. 2.2.1 Negative Covenant. Aimmune covenants that it will not use or practice any of Xencor's rights to and under the Xencor Patents, Xencor Know-How or other intellectual property rights licensed (or sublicensed, as applicable) to it under this ARTICLE 2, except for the purposes expressly permitted in the applicable license grant. Aimmune covenants that it will not research or develop (including Develop) the Antibody itself, including not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a molecule that is neither the Antibody nor a molecule that falls within the definition of a Product. 13 Term Section "Agreement" Preamble "Bankrupt Party" 14.7 "Breaching Party" 13.2 [***] 1.73 "Claim" 11.1 "CMC" 1.66 "Commercialization Data" 5.5 "Confidential Information" 12.1.1 "Controlling Party" 9.4.1(a) "Court" 15.13.3 "Dispute" 15.1 "Effective Date" Preamble "ICH" 1.34 Term Section "Indemnified Party" 11.3.1 "Indemnifying Party" 11.3.1 "Infringement Claim" 9.4.1 "Joint Collaboration Patents" 9.1.1 "Aimmune" Preamble "Aimmune Collaboration Patents" 9.1.1 "Xencor" Preamble "Xencor Collaboration Patents" 9.1.1 "Losses" 11.1 "Packaging and Labeling" 6.2 Term Section "Party" or "Parties" Preamble "Product Trade Dress" 5.4.1 "Product Trademark" 5.4.1 "Recovery" 9.4.2(c)(iv) "Shares" 7.1 "Stock Issuance Agreement" 7.1 "Sublicensee" 2.3.2 "Term" 13.1 "Third Party Patent" 7.3.2(b) "Upfront Payment" 7.1 "VAT" 8.3.3 Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020 2.2.2 No Implied Licenses; Retained Rights. Except as explicitly set forth in this Agreement, Xencor does not grant any license, express or implied, under its intellectual property rights to Aimmune, whether by implication, estoppel or otherwise. 2.2.3 Upstream Agreement. Aimmune acknowledges, understands and agrees that (i) the Xencor Know-How licensed to Aimmune pursuant to Section 2.1 includes certain Know-How licensed to Xencor pursuant to the Upstream Agreement, (ii) the license to such Xencor Know-How constitutes a sublicense under the Upstream Agreement, (iii)
"""

Extract the exact clause related to "Non-Compete" from the excerpt above.

assistant: Aimmune covenants that it will not research or develop (including Develop) the Antibody itself, including not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a molecule that is neither the Antibody nor a molecule that falls within the definition of a Product.